Matrix metalloproteinase contribution in management of cancer proliferation, metastasis and drug targeting

Mol Biol Rep. 2021 Sep;48(9):6525-6538. doi: 10.1007/s11033-021-06635-z. Epub 2021 Aug 11.

Abstract

Matrix metalloproteinases (MMPs) or matrixins, are members of a zinc-dependent endopeptidase family. They cause remodeling of the extracellular matrix (ECM) leading to numerous diseases. MMPs subfamilies possess: collagenases, gelatinases, stromelysins and membrane-type MMPs (MT-MMP). They consist of several domains; pro-peptide, catalytic, linker peptide and the hemopexin (Hpx) domains. MMPs are involved in initiation, proliferation and metastasis of cancer through the breakdown of ECM physical barriers. Overexpression of MMPs is associated with poor prognosis of cancer. This review will discuss both types of MMPs and current inhibitors, which target them in different aspects, including, biosynthesis, activation, secretion and catalytic activity. Several synthetic and natural inhibitors of MMPs (MMPIs) that can bind the catalytic domain of MMPs have been designed including; peptidomimetic, non-peptidomimetic, tetracycline derivatives, off-target MMPI, natural products, microRNAs and monoclonal antibodies.

Keywords: Cancer; Inhibitors; Metalloproteinase; Metastasis; Proliferation.

Publication types

  • Review

MeSH terms

  • Cell Proliferation / drug effects*
  • Drug Delivery Systems / methods*
  • Extracellular Matrix / metabolism
  • Humans
  • Matrix Metalloproteinase Inhibitors / metabolism*
  • Matrix Metalloproteinase Inhibitors / therapeutic use*
  • Matrix Metalloproteinases / chemistry
  • Matrix Metalloproteinases / metabolism*
  • Neoplasm Metastasis
  • Neoplasms / drug therapy*
  • Neoplasms / enzymology*
  • Neoplasms / pathology
  • Prognosis
  • Protein Domains / drug effects

Substances

  • Matrix Metalloproteinase Inhibitors
  • Matrix Metalloproteinases